Actinium Pharmaceuticals, Inc. (ATNM): Sloan-kettering Cance Memorial , 10% owner of Actinium Pharmaceuticals, Inc. sold 148,100 shares on Jun 30, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $1.83 per share for a total value of $268,435.97 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 17, 2016, Sloan-kettering Cance Memorial (10% owner) sold 33,619 shares at $1.90 per share price.On Apr 18, 2016, C. David Nicholson, (director) purchased 5,000 shares at $2.00 per share price.Also, On Apr 18, 2016, Sergio Traversa (director) purchased 3,000 shares at $2.02 per share price.On Apr 18, 2016, Sandesh Seth (director other) purchased 15,000 shares at $2.00 per share price.
Actinium Pharmaceuticals Inc: On Friday, Jul 1, 2016 heightened volatility was witnessed in Actinium Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $1.8 and hit $1.91 on the upside , eventually ending the session at $1.84, with a gain of 3.95% or 0.07 points. The heightened volatility saw the trading volume jump to 6,23,022 shares. The 52-week high of the share price is $3.5 and the company has a market cap of $86 M . The 52-week low of the share price is at $1.52.
Actinium Pharmaceuticals Inc. (Actinium) is a biopharmaceutical company engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company’s products include Actimab-A an antibody-drug construct containing actinium 225 (Ac-225) and Iomab-B an antibody-drug construct containing iodine 131 (I-131). As of December 31 2014 Actinium’s Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. As of December 31 2014 the Company had four product candidates in clinical trials: Actimab-A (HuM195-Ac-225) Iomab-B (BC8-I-131) BC8-Y-90 and BC8-SA. As of December 31 2014 BC8-Y-90 and BC8-SA were in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).